[A17-34] Glecaprevir/pibrentasvir (chronic hepatitis C) – Benefit assessment according to § 35a Social Code Book V
Last updated 02.11.2017
Commission awarded on 01.08.2017 by the Federal Joint Committee (G-BA).
Immune system and infections
Chronic hepatitis C
Due to a lack of data, an added benefit is not proven for any of the 7 therapeutic indications (genotypes, pretreatment)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-33||Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A21-88||Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V||Commission completed|